We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · May 22, 2022

Efficacy and Safety of Oral Tyrosine Kinase 2 Inhibitor PF-06826647 in Managing Moderate to Severe Plaque Psoriasis

Journal of the American Academy of Dermatology


Additional Info

Journal of the American Academy of Dermatology
Oral tyrosine kinase 2 inhibitor PF-06826647 demonstrates efficacy and an acceptable safety profile in participants with moderate-to-severe plaque psoriasis in a phase 2b, randomized, double-blind, placebo-controlled study
J Am Acad Dermatol 2022 Apr 06;[EPub Ahead of Print], C Tehlirian, RSP Singh, V Pradhan, ES Roberts, S Tarabar, E Peeva, MS Vincent, JD Gale

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading